Zkusit zdarma
C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

CCCC
Cena:
$ 3.56
+0.04 (1.14%)
Valuace
70
Růst
45
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics to Participate in Upcoming Conferences

7:00 20-05-2026

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a cli...

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

10:41 15-05-2026

Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed comp...

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

9:11 12-05-2026

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.2 per share versus the Zacks Conse...

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

7:00 12-05-2026

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a cli...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 58.8% in March

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 58.8% in March

4:26 28-03-2026

C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) was the target of a large increase in short i...

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

10:41 27-03-2026

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to thei...

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

7:00 25-03-2026

Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combinatio...

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

10:50 10-03-2026

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcrip...

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

7:49 10-03-2026

C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tig...

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

1:02 09-03-2026

C4 Therapeutics (NASDAQ: CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference t...

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

13:01 06-03-2026

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? ...

C4 Therapeutics to Participate in Upcoming March Conferences

C4 Therapeutics to Participate in Upcoming March Conferences

7:10 23-02-2026

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a cl...

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

7:00 23-02-2026

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027  Phase 1b Trial of Cemsid...

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

7:00 04-02-2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a cl...

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

7:00 14-01-2026

Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 ...

C4 Therapeutics Sees Unusually High Options Volume (NASDAQ:CCCC)

C4 Therapeutics Sees Unusually High Options Volume (NASDAQ:CCCC)

1:46 18-12-2025

C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) saw some unusual options trading activity on ...

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

6:27 26-11-2025

C4 Therapeutics reported a Q3 GAAP EPS loss of –$0.44, missing estimates, but revenue of $11.23M b...

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

10:16 12-11-2025

Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance...

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

9:26 06-11-2025

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.44 per share versus the Zacks Cons...

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

7:00 06-11-2025

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 202...

close

C4 THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

09-02-2026
WATERTOWN, MASS., FEB. 09, 2026 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS TO PARTICIPATE IN THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026

04-02-2026
WATERTOWN, MASS., FEB. 04, 2026 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

26-01-2026
WATERTOWN, MASS., JAN. 26, 2026 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS OUTLINES STRATEGIC MILESTONES TO ADVANCE CEMSIDOMIDE AS A POTENTIAL BEST-IN-CLASS IKZF1/3 DEGRADER AND DISCOVERY STRATEGY FOCUSED ON NOVEL TARGETS IN CLINICALLY VALIDATED PATHWAYS

14-01-2026
CEMSIDOMIDE PHASE 2 MOMENTUM TRIAL ON TRACK TO INITIATE IN Q1 2026; RECOMMENDED PHASE 2 DOSE IS 100 ...
Více zde

C4 THERAPEUTICS TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

25-11-2025
WATERTOWN, MASS., NOV. 25, 2025 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

06-11-2025
COMPLETED EQUITY OFFERING RESULTED IN $125 MILLION IN GROSS PROCEEDS, EXTENDING RUNWAY TO END OF 202...
Více zde

C4 THERAPEUTICS ANNOUNCES PRICING OF $125 MILLION UNDERWRITTEN OFFERING

16-10-2025
$125 MILLION IN UPFRONT PROCEEDS EXPECTED TO FUND NEXT PHASE OF CEMSIDOMIDE MULTIPLE MYELOMA DEVELOP...
Více zde

C4 THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH PFIZER FOR THE COMBINATION OF CEMSIDOMIDE AND ELRANATAMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

01-10-2025
WATERTOWN, MASS., OCT. 01, 2025 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS PRESENTS CEMSIDOMIDE PHASE 1 MULTIPLE MYELOMA DATA SUPPORTING POTENTIAL BEST-IN-CLASS PROFILE AT THE INTERNATIONAL MYELOMA SOCIETY ANNUAL MEETING

20-09-2025
CEMSIDOMIDE IN COMBINATION WITH DEXAMETHASONE ACHIEVED A 50% OVERALL RESPONSE RATE (ORR) AT THE HIGH...
Více zde

C4 THERAPEUTICS HIGHLIGHTS RECENT ACHIEVEMENT IN BIOGEN COLLABORATION

04-09-2025
WATERTOWN, MASS., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A C...
Více zde

C4 THERAPEUTICS TO PRESENT DATA FROM THE PHASE 1 TRIAL OF CEMSIDOMIDE IN MULTIPLE MYELOMA AT THE INTERNATIONAL MYELOMA SOCIETY (IMS) ANNUAL MEETING

03-09-2025
WATERTOWN, MASS., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A C...
Více zde

C4 THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

07-08-2025
CEMSIDOMIDE PHASE 1 DATA IN MULTIPLE MYELOMA ACCEPTED AS AN ORAL PRESENTATION  AT THE INTERNATIONAL...
Více zde

C4 THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

07-05-2025
UPDATED CEMSIDOMIDE MULTIPLE MYELOMA DATA FURTHER DEMONSTRATE COMPELLING RESPONSE RATES AT MULTIPLE ...
Více zde

C4 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

27-02-2025
PLANNING ACTIVITIES ARE ONGOING FOR NEXT PHASE OF CEMSIDOMIDE CLINICAL DEVELOPMENT IN MULTIPLE MYELO...
Více zde

C4 THERAPEUTICS TO PARTICIPATE IN UPCOMING MARCH INVESTOR CONFERENCES

24-02-2025
WATERTOWN, MASS., FEB. 24, 2025 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS PRESENTS CEMSIDOMIDE PHASE 1 DATA AT THE AMERICAN SOCIETY FOR HEMATOLOGY (ASH) ANNUAL MEETING THAT DEMONSTRATED POTENTIAL TO BECOME BEST-IN-CLASS IKZF1/3 DEGRADER

08-12-2024
IN MULTIPLE MYELOMA, CEMSIDOMIDE IN COMBINATION WITH DEXAMETHASONE AT HIGHEST DOSE LEVEL EXPLORED TO...
Více zde

C4 THERAPEUTICS APPOINTS ACCOMPLISHED ONCOLOGY EXECUTIVE STEVE HOERTER TO BOARD OF DIRECTORS

20-11-2024
HOERTER BRINGS OVER THREE DECADES OF ONCOLOGY COMMERCIALIZATION AND LEADERSHIP EXPERIENCE APPOINTMEN...
Více zde

C4 THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

28-10-2024
WATERTOWN, MASS., OCT. 28, 2024 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS APPOINTS PAIGE MAHANEY, PH.D., AS CHIEF SCIENTIFIC OFFICER AND ANNOUNCES RETIREMENT OF STEWART FISHER, PH.D.

15-10-2024
MAHANEY BRINGS MORE THAN 25 YEARS OF PHARMACEUTICAL AND BIOTECH EXPERIENCE OVERSEEING DRUG DISCOVERY...
Více zde

C4 THERAPEUTICS ANNOUNCES PRESENTATIONS AND PARTICIPATION IN 7TH ANNUAL TARGETED PROTEIN DEGRADATION & INDUCED PROXIMITY SUMMIT

09-10-2024
WATERTOWN, MASS., OCT. 09, 2024 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

30-09-2024
WATERTOWN, MASS., SEPT. 30, 2024 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A C...
Více zde

C4 THERAPEUTICS PRESENTS MONOTHERAPY DATA DEMONSTRATING PROOF OF MECHANISM AND EARLY EVIDENCE OF PROOF OF CONCEPT FROM ONGOING CFT1946 PHASE 1 TRIAL IN BRAF V600 MUTANT SOLID TUMORS AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2024

13-09-2024
CFT1946 IS WELL-TOLERATED AT ALL DOSE LEVELS; NO DOSE-LIMITING TOXICITIES CFT1946 ACHIEVES DOSE PROP...
Více zde

C4 THERAPEUTICS TO PRESENT PRELIMINARY CFT1946 MONOTHERAPY PHASE 1 CLINICAL DATA AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2024

08-09-2024
ABSTRACT RELEASED TODAY HIGHLIGHTS FAVORABLE SAFETY PROFILE AND EARLY EVIDENCE OF MONOTHERAPY ANTI-T...
Více zde

C4 THERAPEUTICS APPOINTS VETERAN BIOTECHNOLOGY LEADER STEPHEN FAWELL, PH.D. TO BOARD OF DIRECTORS

03-09-2024
WATERTOWN, MASS., SEPT. 03, 2024 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A C...
Více zde

C4 THERAPEUTICS TO PARTICIPATE IN UPCOMING SEPTEMBER INVESTOR CONFERENCES

29-08-2024
WATERTOWN, MASS., AUG. 29, 2024 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

01-08-2024
PRELIMINARY MONOTHERAPY DATA FROM THE ONGOING CFT1946 PHASE 1 TRIAL IN BRAF V600X SOLID TUMORS TO BE...
Více zde

C4 THERAPEUTICS TO PRESENT PRELIMINARY MONOTHERAPY DATA FROM THE ONGOING PHASE 1 TRIAL OF CFT1946 AS A MINI ORAL PRESENTATION AT THE ESMO CONGRESS 2024

16-07-2024
WATERTOWN, MASS., JULY 16, 2024 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS TO PARTICIPATE IN THE VIRTUAL UBS TARGETED PROTEIN DEGRADATION DAY

08-07-2024
WATERTOWN, MASS., JULY 08, 2024 (GLOBE NEWSWIRE) -- C4 THERAPEUTICS, INC. (C4T) (NASDAQ: CCCC), A CL...
Více zde

C4 THERAPEUTICS APPOINTS RON COOPER AS CHAIRMAN OF THE BOARD OF DIRECTORS

10-06-2024
COOPER BRINGS DECADES OF GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY LEADERSHIP EXPERIENCE BRUCE DOWNEY ...
Více zde

C4 THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

08-05-2024
SUCCESSFULLY DELIVERED FIRST DEVELOPMENT CANDIDATE TO BIOGEN; $8 MILLION PAYMENT EARNED ESTABLISHED ...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-14 00:00:008-KStáhnout
2025-11-06 00:00:008-KStáhnout
2025-11-06 00:00:0010-QStáhnout
2025-10-16 01:00:008-KStáhnout
2025-10-16 00:00:008-KStáhnout
2025-10-01 01:00:008-KStáhnout
2025-10-01 00:00:008-KStáhnout
2025-09-22 01:00:008-KStáhnout
2025-09-22 00:00:008-KStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 01:00:0010-QStáhnout
2025-08-07 00:00:008-KStáhnout
2025-08-07 00:00:0010-QStáhnout
2025-06-18 01:00:008-KStáhnout
2025-06-18 00:00:008-KStáhnout
2025-05-07 01:00:008-KStáhnout
2025-05-07 01:00:0010-QStáhnout
2025-05-07 00:00:008-KStáhnout
2025-05-07 00:00:0010-QStáhnout
2025-04-14 01:00:008-KStáhnout
2025-04-14 00:00:008-KStáhnout
2025-02-27 00:00:008-KStáhnout
2025-02-27 00:00:0010-KStáhnout
2025-02-26 23:00:008-KStáhnout
2025-02-26 23:00:0010-KStáhnout
2025-01-14 00:00:008-KStáhnout
2025-01-13 23:00:008-KStáhnout
2024-12-09 00:00:008-KStáhnout
2024-12-08 23:00:008-KStáhnout
2024-11-20 00:00:008-KStáhnout
2024-11-19 23:00:008-KStáhnout
2024-10-31 00:00:008-KStáhnout
2024-10-31 00:00:0010-QStáhnout
2024-10-30 23:00:008-KStáhnout
2024-10-30 23:00:0010-QStáhnout
2024-10-15 01:00:008-KStáhnout
2024-10-15 00:00:008-KStáhnout
2024-10-11 01:00:008-KStáhnout
2024-10-11 00:00:008-KStáhnout
2024-09-03 01:00:008-KStáhnout
2024-09-03 00:00:008-KStáhnout
2024-08-01 01:00:008-KStáhnout
2024-08-01 01:00:0010-QStáhnout
2024-08-01 00:00:008-KStáhnout
2024-08-01 00:00:0010-QStáhnout
2024-06-21 01:00:008-KStáhnout
2024-06-21 00:00:008-KStáhnout
2024-06-10 01:00:008-KStáhnout
2024-06-10 00:00:008-KStáhnout
2024-05-08 01:00:008-KStáhnout
2024-05-08 01:00:0010-QStáhnout
2024-05-08 00:00:008-KStáhnout
2024-05-08 00:00:0010-QStáhnout
2024-03-08 00:00:008-KStáhnout
2024-03-07 23:00:008-KStáhnout
2024-03-04 00:00:008-KStáhnout
2024-03-03 23:00:008-KStáhnout
2024-02-22 00:00:008-KStáhnout
2024-02-22 00:00:0010-KStáhnout
2024-02-21 23:00:008-KStáhnout
2024-02-21 23:00:0010-KStáhnout
2024-01-11 00:00:008-KStáhnout
2024-01-10 23:00:008-KStáhnout
2024-01-09 00:00:008-KStáhnout
2024-01-08 23:00:008-KStáhnout
2023-12-12 00:00:008-KStáhnout
2023-12-11 23:00:008-KStáhnout
2023-11-20 00:00:008-KStáhnout
2023-11-19 23:00:008-KStáhnout
2023-11-01 00:00:008-KStáhnout
2023-11-01 00:00:0010-QStáhnout
2023-10-31 23:00:008-KStáhnout
2023-10-31 23:00:0010-QStáhnout
2023-09-05 01:00:008-KStáhnout
2023-09-05 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-06-20 01:00:008-KStáhnout
2023-06-20 00:00:008-KStáhnout
2023-05-30 01:00:008-KStáhnout
2023-05-30 00:00:008-KStáhnout
2023-05-04 01:00:008-KStáhnout
2023-05-04 01:00:0010-QStáhnout
2023-05-04 00:00:008-KStáhnout
2023-05-04 00:00:0010-QStáhnout
2023-02-23 00:00:008-KStáhnout
2023-02-23 00:00:0010-KStáhnout
2023-02-22 23:00:008-KStáhnout
2023-02-22 23:00:0010-KStáhnout
2023-02-02 00:00:008-KStáhnout
2023-02-01 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-11-03 00:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:008-KStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:008-KStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-08-02 01:00:008-KStáhnout
2022-08-02 00:00:008-KStáhnout
2022-06-24 01:00:008-KStáhnout
2022-06-24 00:00:008-KStáhnout
2022-06-17 01:00:008-KStáhnout
2022-06-17 00:00:008-KStáhnout
2022-05-16 01:00:008-KStáhnout
2022-05-16 00:00:008-KStáhnout
2022-05-05 01:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:008-KStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-04-08 01:00:008-KStáhnout
2022-04-08 00:00:008-KStáhnout
2022-03-16 00:00:008-KStáhnout
2022-03-15 23:00:008-KStáhnout
2022-02-24 00:00:008-KStáhnout
2022-02-24 00:00:0010-KStáhnout
2022-02-23 23:00:008-KStáhnout
2022-02-23 23:00:0010-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-11-30 00:00:008-KStáhnout
2021-11-29 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-08-11 01:00:008-KStáhnout
2021-08-11 01:00:0010-QStáhnout
2021-08-11 00:00:008-KStáhnout
2021-08-11 00:00:0010-QStáhnout
2021-06-21 01:00:008-KStáhnout
2021-06-21 00:00:008-KStáhnout
2021-06-14 01:00:008-KStáhnout
2021-06-14 00:00:008-KStáhnout
2021-06-07 01:00:008-KStáhnout
2021-06-07 00:00:008-KStáhnout
2021-05-26 01:00:008-KStáhnout
2021-05-26 00:00:008-KStáhnout
2021-05-20 01:00:008-KStáhnout
2021-05-20 00:00:008-KStáhnout
2021-05-13 01:00:008-KStáhnout
2021-05-13 01:00:0010-QStáhnout
2021-05-13 00:00:008-KStáhnout
2021-05-13 00:00:0010-QStáhnout
2021-04-30 01:00:008-KStáhnout
2021-04-30 00:00:008-KStáhnout
2021-03-11 00:00:008-KStáhnout
2021-03-11 00:00:0010-KStáhnout
2021-03-10 23:00:008-KStáhnout
2021-03-10 23:00:0010-KStáhnout
2021-01-12 00:00:008-KStáhnout
2021-01-11 23:00:008-KStáhnout
2021-01-06 00:00:008-KStáhnout
2021-01-05 23:00:008-KStáhnout
2020-11-19 00:00:008-KStáhnout
2020-11-18 23:00:008-KStáhnout
2020-11-12 00:00:008-KStáhnout
2020-11-12 00:00:0010-QStáhnout
2020-11-11 23:00:008-KStáhnout
2020-11-11 23:00:0010-QStáhnout
2020-10-06 01:00:008-KStáhnout
2020-10-06 00:00:008-KStáhnout
preloader